Healthcare stocks were mixed, with the NYSE Healthcare Sector
Index slipping 0.2% and shares of healthcare companies in the
S&P 500 rising 0.1% as a group.
In company news, Northwest Biotherapeutics (
) shares rose Monday after the oncology care company received a
pair of regulatory approvals from German authorities for its
DCVax-L treatment for glioma brain cancers.
The Paul Ehrlich Institute approved a "Hospital Exemption" early
access program under Section 4b of German Drug Law, allowing the
company to provide the experimental drug treat both Glioblastoma
multiforme and lower grade gliomas outside clinical trials as well
as charging full price for the medication.
The regulatory body also cleared DCVax-L for reimbursement. The
initial approvals have five-year terms.
NWBO shares are up nearly 13% at $6.83 apiece in recent trade,
pushing to a new intra-day high. The stock has a 52-week range of
$2.98 to $20.00 a share.
In other sector news,
(+) RGDO, (+23.3%) U.S. Food and Drug Administration designates
the company's REG1 anticoagulant therapy with fast-track
development status for use in patients with coronary artery disease
during percutaneous coronary interventions.
(-) BONE, (-4.0%) Closes on $4 mln in additional funding from
OrbiMed, issuing 1.5 mln of its shares to the privately held
medical device and diagnostics company. Other terms are unchanged
from the companies' $20 mln term loan in August 2012.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.